ALNY
Alnylam Pharmaceuticals, Inc.
ALNY's fundamentals are strong: revenue grew 56% and its operating margin rose 11 points to 20%. At 8.0x earnings, it's trading less than half its usual 76x. Analysts expect that strong growth to continue, though they disagree widely on how much.
HIMS
Hims & Hers Health, Inc.
There isn't enough reported data to score HIMS yet.
ALNY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
ALNY's revenue, profitability, cash flow and balance sheet are all currently healthy.
HIMS Fundamentals
| Metric | Status |
|---|---|
| Strong | |
| Weak | |
| Stable | |
| Strong |
HIMS's revenue and balance sheet are currently strong, and its cash flow is stable, but its profitability is weak.
ALNY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 8x | $157 | — |
| Forward | 22x | $157 | — |
| Cheap | 41x | $800 | +411% |
| Fair | 76x | $1,489 | +851% |
| Expensive | 1,731x | $33,895 | +21538% |
Historical ranges are pointers, not guarantees.
ALNY's PE is in its cheap range at 8.0x. On analysts' estimates for next year's earnings, today's price would be 22x.
HIMS PE Valuation
HIMS has no meaningful PE right now: it lost money over the past year.
ALNY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly deteriorating | |
| Strong growth | |
| Strong growth | |
| Weakening | |
| Limited | |
| Low |
Analysts expect strong earnings and revenue growth for ALNY, but weaker profitability. However, they disagree widely on these estimates.
HIMS Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Turning to a loss | |
| Strong growth | |
| Stable | |
| Limited | |
| Low |
Analysts expect HIMS's revenue to grow, but its earnings to decline. However, they disagree widely on these estimates.
ALNY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $7.04 | -64% |
| Q3 2026 | $19.58 | +8413% |
| Q2 2026 | $5.70 | +$8.18 |
| Q1 2026 | $3.98 | +$6.08 |
| Q4 2025 | $2.03 | +$4.21 |
| Q3 2025 | $0.23 | +$2.81 |
| Q2 2025 | -$2.48 | -$1.92 |
| Q1 2025 | -$2.10 | +$0.54 |
| Q4 2024 | -$2.18 | +$1.34 |
ALNY has the edge over HIMS on earnings quality, reporting a profit while its opponent remains loss making.
HIMS Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.83 | -257% |
| Q2 2026 | -$0.63 | -180% |
| Q1 2026 | -$0.09 | -113% |
| Q4 2025 | $0.51 | -3.8% |
| Q3 2025 | $0.53 | +20% |
| Q2 2025 | $0.79 | +888% |
| Q1 2025 | $0.68 | +$0.69 |
| Q4 2024 | $0.53 | +$0.64 |
HIMS has swung to a loss: it lost $0.83 per share over the past year, after a profit the year before.
ALNY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $1.5B | +17% |
| Q2 2026 | $1.3B | +67% |
| Q1 2026 | $1.2B | +96% |
| Q4 2025 | $1.1B | +85% |
| Q3 2025 | $1.2B | +149% |
| Q2 2025 | $773.7M | +17% |
| Q1 2025 | $594.2M | +20% |
| Q4 2024 | $593.2M | +35% |
ALNY has the edge over HIMS on sales, with stronger typical year-over-year growth.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 24% | -5.7 points |
| Q2 2026 | 18% | +20 points |
| Q1 2026 | 23% | +20 points |
| Q4 2025 | 12% | +30 points |
| Q3 2025 | 29% | +45 points |
| Q2 2025 | -2.1% | -9.5 points |
| Q1 2025 | 3% | +12 points |
| Q4 2024 | -18% | +8.7 points |
ALNY has the edge over HIMS on profitability, with a higher operating margin.
HIMS Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $890.4M | +49% |
| Q2 2026 | $753.2M | +38% |
| Q1 2026 | $608.1M | +3.8% |
| Q4 2025 | $617.8M | +28% |
| Q3 2025 | $599M | +49% |
| Q2 2025 | $544.8M | +73% |
| Q1 2025 | $586M | +111% |
| Q4 2024 | $481.1M | +95% |
HIMS's revenue has grown year over year every quarter since late 2021: $890M last quarter, up 49% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -7.4% | -9.4 points |
| Q2 2026 | -13% | -18 points |
| Q1 2026 | -13% | -23 points |
| Q4 2025 | 1.5% | -2.4 points |
| Q3 2025 | 2% | -3.6 points |
| Q2 2025 | 4.9% | +1.4 points |
| Q1 2025 | 9.9% | +6.3 points |
| Q4 2024 | 3.9% | +4 points |
HIMS's operating margin was −7.4% last quarter, down 9.4 points from the same quarter a year ago.
ALNY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $271.2M | -13% |
| Q2 2026 | $292M | +109% |
| Q1 2026 | $48.7M | +$176M |
| Q4 2025 | $140.3M | +$244M |
| Q3 2025 | $313M | +692% |
| Q2 2025 | $139.4M | +20% |
| Q1 2025 | -$127.3M | -$32.8M |
| Q4 2024 | -$103.8M | -$58.7M |
ALNY has burned cash in most quarters: $752M over the past year, about three times what it generated the year before.
HIMS Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $26M | -67% |
| Q2 2026 | -$68.2M | +$1.3M |
| Q1 2026 | $53.1M | +5.9% |
| Q3 2025 | $79.3M | -7% |
| Q2 2025 | -$69.5M | -230% |
| Q1 2025 | $50.1M | +94% |
| Q3 2024 | $85.3M | +238% |
| Q2 2024 | $53.6M | +219% |
HIMS has the edge over ALNY on cash flow, with more consistent year-over-year improvement.
ALNY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | -0.2% | -241K shares |
| 1 year | +0.5% | +692K shares |
| 3 years | +5.1% | +6.7M shares |
| 5 years | +16% | +18.9M shares |
| Available history | +24% | +26.3M shares |
ALNY has 138M diluted shares, up 0.5% from a year ago.
HIMS Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.9% | +2.1M shares |
| 1 year | -6% | -14.9M shares |
| 3 years | +11% | +23.7M shares |
| 5 years | +17% | +33.8M shares |
HIMS has the edge over ALNY on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q4 2025 | $80.5M |
| Q3 2025 | $9.5M |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | $5M |
| Q3 2024 | $30M |
| Q2 2024 | $19.9M |
| Q1 2024 | $28.1M |
ALNY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | -1.7x | Net Cash |
| Q2 2026 | -1.6x | Net Cash |
| Q1 2026 | -2.1x | Net Cash |
| Q4 2025 | -3.0x | Net Cash |
| Q3 2025 | -4.6x | Net Cash |
| Q2 2024 | -6.1x | Net Cash |
ALNY has more cash than debt.
HIMS Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q1 2026 | -5.9x | Net Cash |
| Q4 2025 | -1.4x | Net Cash |
| Q3 2025 | -2.2x | Net Cash |
| Q2 2025 | -7.3x | Net Cash |
| Q1 2025 | -2.1x | Net Cash |
| Q4 2024 | -2.8x | Net Cash |
| Q3 2024 | -2.9x | Net Cash |
| Q2 2024 | -5.5x | Net Cash |
HIMS has more cash than debt.
ALNY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 28.6 | Oversold |
| Stochastic | 2.9 | Oversold |
ALNY's weekly RSI is 29 (oversold) and its Stochastic is 3 (oversold).
HIMS Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 36.0 | Neutral |
| Stochastic | 23.0 | Neutral |
HIMS's weekly RSI is 36 (neutral) and its Stochastic is 23 (neutral).
ALNY PE vs Healthcare Sector
| Metric | ALNY | Sector median | Relative |
|---|---|---|---|
| PE | 8x | 26x | 69% below |
| PE % | 2 | 29 | 27 pts below |
ALNY is trading at 8.0x earnings, a 69% discount to the Healthcare sector's median of 26x.
HIMS PE vs Healthcare Sector
| Metric | HIMS | Sector median | Relative |
|---|---|---|---|
| PE | N/A | 26x | — |
HIMS has no meaningful PE right now: it lost money over the past year.
ALNY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $205.2 | 24% below |
| 20 week MA | $233.7 | 33% below |
| 50 week MA | $293.0 | 47% below |
| 100 week MA | $314.6 | 50% below |
| 200 week MA | $257.7 | 39% below |
ALNY is in a downtrend: it's below all five of its weekly moving averages, and 39% below its 200-week average.
HIMS Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $27.3 | 28% below |
| 20 week MA | $29.2 | 32% below |
| 50 week MA | $27.7 | 29% below |
| 100 week MA | $35.9 | 45% below |
| 200 week MA | $24.4 | 19% below |
HIMS is in a downtrend: it's below all five of its weekly moving averages, and 19% below its 200-week average.
ALNY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $117.5 | $137.6 | +17% |
| 2021 | $137.6 | $194.4 | +41% |
| 2022 | $194.4 | $237.9 | +22% |
| 2023 | $237.9 | $191.4 | -20% |
| 2024 | $191.4 | $238.0 | +24% |
| 2025 | $238.0 | $400.6 | +68% |
| 2026 YTD | $400.6 | $156.7 | -61% |
ALNY is down 61% so far in 2026, after finishing higher in five of the previous six years.
HIMS Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $9.89 | $15.0 | +51% |
| 2021 | $15.0 | $6.65 | -56% |
| 2022 | $6.65 | $6.43 | -3.3% |
| 2023 | $6.43 | $8.90 | +38% |
| 2024 | $8.90 | $26.6 | +198% |
| 2025 | $26.6 | $34.3 | +29% |
| 2026 YTD | $34.3 | $19.7 | -42% |
HIMS has the edge over ALNY on returns for 2026, with the stronger performance.